Merck Pfizer Metsera Lundbeck Newsletter
- November 14, 2024 - Key developments in biotech, including Moderna's stock decline, rising GLP-1 adoption, Kura Oncology's FDA approval, and Merck's notable acquisition of cidara Therapeutics.
- Moderna continues to face headwinds, with its stock price reflecting investor concerns about its future beyond COVID-19 vaccines.
- the STATus Report video series provides a detailed breakdown of the factors contributing to Moderna's current situation, including challenges in clinical trial results and evolving market dynamics.
“`html
biotech Roundup: Moderna’s Struggles, GLP-1 Usage, and Merck’s $9.2B Acquisition
Table of Contents
November 14, 2024 – Key developments in biotech, including Moderna’s stock decline, rising GLP-1 adoption, Kura Oncology’s FDA approval, and Merck’s notable acquisition of cidara Therapeutics.
Moderna’s Ongoing Challenges
Moderna continues to face headwinds, with its stock price reflecting investor concerns about its future beyond COVID-19 vaccines. The company is working to diversify its pipeline, but faces significant competition and the inherent risks of drug development. Recent analysis suggests the market is questioning Moderna’s ability to successfully transition into a broader mRNA therapeutics company.
the STATus Report video series provides a detailed breakdown of the factors contributing to Moderna’s current situation, including challenges in clinical trial results and evolving market dynamics.
GLP-1s: Rapidly Increasing Adoption
A new KFF poll reveals that approximately 1 in 8 Americans (12.5%) have now used a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily for weight loss and diabetes management. This represents a considerable increase in adoption over the past year, driven by the popularity of drugs like Ozempic and Wegovy.
| GLP-1 Usage in the US (KFF Poll, Nov 2024) | |
|---|---|
| Total US Adults Using GLP-1s: | 12.5% |
| For Weight Loss: | 7.4% |
| For Diabetes: | 5.1% |
The rapid growth of the GLP-1 market is prompting increased scrutiny from regulators and healthcare providers regarding access, affordability, and potential long-term effects. Supply chain issues have also been reported, impacting availability for some patients.
Kura Oncology Receives FDA Approval
kura Oncology announced FDA approval for its drug, KO-539, for the treatment of acute myeloid leukemia (AML). This approval marks a significant milestone for the company and provides a new treatment option for patients with this aggressive blood cancer. KO-539 targets a specific genetic mutation commonly found in AML, offering a more targeted approach to therapy.
Pharma Consolidation Continues: Merck Acquires Cidara Therapeutics
Merck announced its acquisition of Cidara Therapeutics for $9.2 billion. Cidara’s lead asset is an experimental influenza therapy, which merck intends to integrate into its expanding infectious disease pipeline. This acquisition is strategically timed as Merck prepares for the loss of patent exclusivity on its blockbuster cancer drug,Keytruda,and seeks to diversify its revenue streams.
The deal underscores the ongoing trend of pharmaceutical companies acquiring smaller biotech firms to bolster their pipelines and secure future growth. Analysts predict further consolidation in the biotech sector as large pharma companies seek innovative therapies and technologies.